Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Wednesday, February 10, 2010, 6:53am EST - Canadian Markets open in 2 hours and 37 minutes.
To create a watchlist or portfolio of shares,
Sign-in
or
Register
Finance Home
Investing
Volume Leaders
Local Markets
US Markets
International Markets
Advances & Declines
ETFs
Income Trust News
News & Opinion
Markets
Industry
RSS-My Yahoo!
Personal Finance
Banking & Budgeting
Calculators
Insurance
Retirement
Taxes
My Portfolios
Sign In to Create/Edit My Portfolios
Get Quotes
Symbol Lookup
Exchanges
Amgen Inc. (AMGN)
On Feb 9:
57.21 USD
0.00 (0.00%)
MORE ON AMGN
Quotes
Summary
Options
Historical Prices
Charts
Interactive
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Major Holders
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheets
Cash Flow
Amgen Inc.
(NasdaqNM:AMGN) Delayed quote data
Last Trade:
57.21 USD
Trade Time:
Feb 9
Change:
0.00 (0.00%)
Prev Close:
57.21
Open:
N/A
Bid:
54.80
x 500
Ask:
N/A
1y Target Est:
59.82
Day's Range:
N/A - N/A
52wk Range:
44.96 - 64.76
Volume:
0
Avg Vol
(3m)
:
6,527,030
Market Cap:
56.92B
P/E
(ttm)
:
20.29
EPS
(ttm)
:
2.82
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Free Annual Reports
Add AMGN to Portfolio
Download Data
HEADLINES
U.S. Stocks Gain on Hopes for Greece Aid
at The Wall Street Journal Online
(Tue 10:09pm)
Amgen's denosumab offers hope in rare bone tumours
at Reuters
(Tue 7:01pm)
Coca-Cola and industrials help stocks rally
at FT.com
(Tue 5:20pm)
Amgen, Apple: Money Flow Leaders (AMGN, AAPL)
at The Wall Street Journal Online
(Tue 4:25pm)
Dow Over 10,000; Greek Rescue Plan Pondered
at SmartMoney.com
(Tue 3:17pm)
Don't Invest Another Penny
at Motley Fool
(Tue 12:41pm)
Bone Up On This Potential Blockbuster
at Motley Fool
(Tue 11:58am)
Amgen sees positive data in bone drug study
AP
(Tue 10:58am)
Positive Results on Amgen Drug
Zacks.com
(Tue 10:49am)
Indications: U.S. futures recover after sub-10,000 Dow close
at MarketWatch
(Tue 8:59am)
UPDATE - Amgen: denosumab prostate cancer trial meets goals
at Reuters
(Mon, Feb 8)
More Headlines for AMGN...
ANALYST
EPS Est (next year)
(Dec-08)
:
4.23
EPS Est (in 2 years)
(Dec-09)
:
4.61
Avg Rec (current)*:
2.6
PEG Ratio:
1.10
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion
-
Estimates
BUSINESS SUMMARY
Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology.
Full Company Profile
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Symbol Lookup
Latest News
Canadian Indices